Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.
사설/논평
0/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
APA
Munir T, Cairns DA, Hillmen P (2025). Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.. The New England journal of medicine, 393(22), 2280. https://doi.org/10.1056/NEJMc2515262
MLA
Munir T, et al.. "Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.." The New England journal of medicine, vol. 393, no. 22, 2025, pp. 2280.
PMID
41337731 ↗
같은 제1저자의 인용 많은 논문 (2)
- Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort.